

Company name: JMS Co., Ltd.  
Name of representative: Ryuji Katsura, President and Representative Director  
(Securities code: 7702; Tokyo Stock Exchange)  
Inquiries: Jo Sueda, Executive Officer, Head of Corporate Affairs Division  
(Telephone: +81-82-243-5844)

## Notice regarding Differences between Consolidated Financial Forecasts and Actual Results for the First Half of the Fiscal Year Ending March 31, 2024 and Revision of Forecast for Consolidated Financial Results for the Full Fiscal Year

Announcement of the following discrepancies between the consolidated financial results forecast for the first half of the fiscal year ending March 31, 2024 which was announced on May 12, 2023, and the actual results for the same period disclosed today.

In addition, we would like to announce the following revisions made to its forecast for the consolidated financial results for the full fiscal year ending March 31, 2024, in view of the trend in its recent business performance.

### 1. Difference between Consolidated Financial Forecast and Actual Results for the First Half of the Fiscal Year Ending March 31, 2024 (April 1, 2023 - September 30, 2023)

(Unit: million yen)

|   | Net sale | Operating profit | Ordinary profit | Profit attributable to owners of parent | Earnings per share |
|---|----------|------------------|-----------------|---|--------------------|
| Forecast previously announced (A)   | 32,400   | 350              | 400             | 300                                     | 12.27 yen          |
| Actual results announced today (B)  | 31,248   | (320)            | (135)           | (258)                                   | (10.58) yen        |
| Difference (B - A)  | (1,151)  | (670)            | (535)           | (558)                                   |                    |
| Difference (%)  | (3.6)    | —                | —               | —                                       |                    |
| <Reference>Actual results for first half of previous fiscal year ended March 31, 2023 | 29,975   | (44)             | 56              | (68)                                    | (2.80) yen         |

2. Revision to consolidated Financial Forecast for the fiscal year ending March 31, 2024 (April 1, 2023 to March 31, 2024)

(Unit: million yen)

|  | Net sale | Operating profit | Ordinary profit | Profit attributable to owners of parent | Earnings per share |
|--|----------|------------------|-----------------|---|--------------------|
| Forecast previously announced (A)  | 67,000   | 1,000            | 1,100           | 800                                     | 32.72 yen          |
| Forecast announced today (B)   | 64,500   | 100              | 400             | 100                                     | 4.08 yen           |
| Difference (B – A)   | (2,500)  | (900)            | (700)           | (700)                                   |                    |
| Difference (%)   | (3.7)    | (90.0)           | (63.6)          | (87.5)                                  |                    |
| <Reference> Actual results for previous fiscal year ended March 31, 2023 | 63,740   | 724              | 586             | 281                                     | 11.50 yen          |

3. Reasons for the difference and revision

Net sales for the first half of the fiscal year ending March 31, 2024 was lower than the previous forecast due to a decline in domestic equipment demand and inventory adjustments by our major overseas customers in Dialysis field, despite increased sales of Closed Drug Mixing/Infusion Systems which are being promoted as a focus business as well as sales in Transfusion fields grew steadily due to a recovery in overseas demand. As for profits, despite proceeding price pass-through mainly on some products for domestic market, impact of sales decrease and soaring raw material and electricity costs as well as adverse effects of foreign exchange, resulting in lower than previously forecasted operating profit, ordinary profit, and net income attributable to owners of parent company.

Despite continued efforts to improve profitability by expanding sales, reviewing prices, reducing manufacturing costs, and lowering expenses through efficient business activities, we have revised its Financial Forecast for the full fiscal year ending March 31, 2024, in view of the recent trend of yen depreciation and crude oil prices, in addition to the actual results for the first half of the fiscal year.

\*The above forecast is based on currently available information as of the announcement of this material and actual results may differ from the projected figures due to various factors.

END